Unknown

Dataset Information

0

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies.


ABSTRACT: Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibit aberrantly activated pathways and/or to unleash antigen (Ag)-specific immune responses. Nonetheless, mAb-mediated targeted pressure often fails due to escape mechanisms, mainly Ag loss/downregulation, ultimately providing therapy resistance. Hence, in order to target multiple Ag at the same time, and to facilitate cancer-immune cells interactions, bispecific antibodies (bsAbs) have been developed and are being tested in clinical trials, yielding variable safety/efficacy results based on target selection and their structure. While in hematologic cancers the bsAb blinatumomab recently reached the Food and Drug Administration (FDA)-approval for B Cell Acute Lymphoblastic Leukemia, bsAbs use in solid tumors faces considerable challenges, such as target Ag selection, biodistribution, and the presence of an immune-suppressive tumor microenvironment (TME). This review will focus on the state-of-the art, the design, and the exploitation of bsAbs against solid malignancies, delineating their mechanisms of action, major pitfalls, and future directions.

SUBMITTER: Antonarelli G 

PROVIDER: S-EPMC8468026 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6766786 | biostudies-literature
| S-EPMC8131538 | biostudies-literature
| S-EPMC9694302 | biostudies-literature
| S-EPMC10526328 | biostudies-literature
| S-EPMC7221185 | biostudies-literature
| S-EPMC5607507 | biostudies-literature
| S-EPMC9405798 | biostudies-literature
| S-EPMC8684149 | biostudies-literature
| S-EPMC8422067 | biostudies-literature
| S-EPMC5916246 | biostudies-literature